Intralymphatic immunotherapy: From the rationale to human applications

Current Topics in Microbiology and Immunology

Volumn 352, Issue 1, 2011, Pages 71-84

  Senti, Gabriela ^a   Johansen, Pål ^b   Kündig, Thomas M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIGEN; BCG VACCINE; BEE VENOM; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; ISCOM; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MESSENGER RNA; NAKED DNA; PHOSPHOLIPASE A2; POLLEN EXTRACT; PROTEIN P27; RNA VACCINE; TUMOR CELL VACCINE; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS VACCINE; CORE PROTEIN; CORE PROTEIN 27; IMMUNOLOGIC AGENT; IMMUNOLOGICAL ADJUVANT; MHC CLASS 1 BINDING PEPTIDE; MRNA VACCINE; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; B LYMPHOCYTE; BCG VACCINATION; BEE VENOM ALLERGY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION PAIN; INNATE IMMUNITY; INSECT ALLERGY; INTRALYMPHATIC IMMUNOTHERAPY; LOW DRUG DOSE; LYMPH NODE; LYMPH VESSEL; MELANOMA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN TARGETING; RHINOCONJUNCTIVITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CYTOKINE PRODUCTION; DRUG DISTRIBUTION; GRASS POLLEN INDUCED RHINOCONJUNTIVITIS; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSECT BITE; POLLEN ALLERGY; SENSITIZATION; SUBCUTANEOUS IMMUNOTHERAPY; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; LYMPH NODES; MICE; RHINITIS, ALLERGIC, SEASONAL; TUMOR CELLS, CULTURED; VACCINES; VACCINES, DNA;

MUS;

EID: 80053556713     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_133     Document Type: Article

References (72)

1. Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M et al (2010) Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther 18:651-659
2. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC (2005) Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third national health and nutrition examination survey. J Allergy Clin Immunol 116:377-383 (Pubitemid 41096546)
3. Barratt-Boyes SM, Watkins SC, Finn OJ (1997) Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection. Adv Exp Med Biol 417:71-75 (Pubitemid 27427722)
4. Barratt-Boyes SM, Zimmer MI, Harshyne LA, Meyer EM, Watkins SC, Capuano S III et al (2000) Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 164:2487-2495 (Pubitemid 30115478)
5. Bogers WM, Bergmeier LA, Ma J, Oostermeijer H, Wang Y, Kelly CG et al (2004a) A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. Aids 18:25-36 (Pubitemid 38402314)
6. Bogers WM, Bergmeier LA, Oostermeijer H, ten Haaft P, Wang Y, Kelly CG et al (2004b) CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection. Vaccine 22:2974-2984 (Pubitemid 39037197)
7. Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S et al (2008) Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 181:2990-2998
8. Bousquet J, Lockey R, Malling HJ (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102:558-562
9. Brown K, Gao W, Alber S, Trichel A, Murphey-Corb M, Watkins SC et al (2003) Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 171:6875-6882 (Pubitemid 37532123)
10. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C (2007) Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 62:197-206 (Pubitemid 46090303)
11. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN et al (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12-17 (Pubitemid 36070411)
12. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23:1407-1413 (Pubitemid 41679393)
13. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al (1999) Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475 (Pubitemid 29372886)
14. Finerty S, Stokes CR, Gruffydd-Jones TJ, Hillman TJ, Barr FJ, Harbour DA (2001) Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20:49-58 (Pubitemid 32905313)
15. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166:4254-4259 (Pubitemid 32224961)
16. Frey JR, Wenk P (1957) Experimental studies on the pathogenesis of contact eczema in the guinea-pig. Int Arch Allergy Appl Immunol 11:81-100
17. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM (1996) Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 97:579-587 (Pubitemid 26062755)
18. Greter M, Hofmann J, Becher B (2009) Neo-lymphoid aggregates in the adult liver can initiate potent cell-mediated immunity. PLoS Biol 7:e1000109
19. Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR et al (2006) Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12:5801-5808 (Pubitemid 44629612)
20. Guidry AJ, O'Brian CN, Oliver SP, Dowlen HH, Douglass LW (1994) Effect of whole Staphylococcus aureus and mode of immunization on bovine opsonizing antibodies to capsule. J Dairy Sci 77:2965-2974
21. Heinzerling L, Basch V, Maloy K, Johansen P, Senti G, Wuthrich B et al (2006) Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine 24:1389-1394 (Pubitemid 43222048)
22. ISAAC (The International Study of Asthma and Allergies in Childhood) Steering Committee (1998) Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjuncti-vitis, and atopic eczema: ISAAC. Lancet 351:1225-1232
23. Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K et al (2005) Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 35:568-574 (Pubitemid 40331333)
24. Juillard GJ, Boyer PJ (1977) Intralymphatic immunization: current status. Eur J Cancer 13:439-440 (Pubitemid 8088478)
25. Juillard GJ, Boyer PJ, Snow HD (1976) Intralymphatic infusion of autochthonous tumor cells in canine lymphoma. Int J Radiat Oncol Biol Phys 1:497-503
26. Juillard GJ, Boyer PJ, Yamashiro CH, Snow HD, Weisenburger TH, McCarthy T et al (1977) Regional intralymphatic infusion (ILI) of irradiated tumor cells with evidence of distant effects. Cancer 39:126-130 (Pubitemid 8028989)
27. Juillard GJ, Boyer PJ, Yamashiro CH (1978) A phase I study of active specific intralymphatic immunotherapy (ASILI). Cancer 41:2215-2225 (Pubitemid 8370192)
28. Juillard GJ, Boyer PJ, Niewisch H, Hom M (1979) Distribution and consequences of cell suspensions following intralymphatic infusion. Bull Cancer 66:217-228
29. -/-mutant mice). J Exp Med 185:2157-2170 (Pubitemid 27265999)
30. Kawabata S, Miller CJ, Lehner T, Fujihashi K, Kubota M, McGhee JR et al (1998) Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus in rhesus macaques. J Infect Dis 177:26-33 (Pubitemid 28030430)
31. Klavinskis LS, Bergmeier LA, Gao L, Mitchell E, Ward RG, Layton G et al (1996) Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 157:2521-2527 (Pubitemid 126450465)
32. Koopman G, Bogers WM, van Gils M, Koornstra W, Barnett S, Morein B et al (2007) Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 79:474-482 (Pubitemid 46564344)
33. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031-9040
34. Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H et al.(1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343-1347
35. Lehner T, Bergmeier LA, Tao L, Panagiotidi C, Klavinskis LS, Hussain L et al (1994) Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 153:1858-1868 (Pubitemid 24251131)
36. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L et al (1996) Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2:767-775 (Pubitemid 26225092)
37. Lehner T, Mitchell E, Bergmeier L, Singh M, Spallek R, Cranage M et al (2000) The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 30:2245-2256
38. Lesimple T, Moisan A, Carsin A, Ollivier I, Mousseau M, Meunier B et al (2003) Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects. Cancer Immunol Immunother 52:438-444 (Pubitemid 36831365)
39. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarriere N et al (2006) Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 12:7380-7388 (Pubitemid 46095412)
40. Lockey RF (2001) "ARIA": global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 108:497-499 (Pubitemid 32978015)
41. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC (1987) Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 79:660-677
42. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC (1990) The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 86:775-780
43. + hematopoietic progenitor cells. Cancer Immunol Immunother 48:118-122 (Pubitemid 29287296)
44. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM et al (2001) Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 98:3299-3303 (Pubitemid 32220840)
45. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38:1404-1413
46. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM (2009a) Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 150:59-65
47. Martinez-Gomez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C et al (2009b) Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 64:172-178
48. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunc-tivitis (the PAT-study). J Allergy Clin Immunol 109:251-256 (Pubitemid 34158289)
49. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56-58 (Pubitemid 29062955)
50. Nilsson BO, Svalander PC, Larsson A (1987) Immunization of mice and rabbits by intrasplenic deposition of nanogram quantities of protein attached to Sepharose beads or nitrocellulose paper strips. J Immunol Methods 99:67-75 (Pubitemid 17089976)
51. Norman PS (2004) Immunotherapy: 1999-2004. J Allergy Clin Immunol 113:1013-1023, quiz 24 (Pubitemid 38857976)
52. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J et al (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T cell induction. Nature 411:1058-1064 (Pubitemid 32612331)
53. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S (2001) Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31:1392-1397 (Pubitemid 32823876)
54. Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A (2000) Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 84:241-243 (Pubitemid 30141606)
55. Quillien V, Moisan A, Carsin A, Lesimple T, Lefeuvre C, Adamski H et al (2005) Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 32:731-741 (Pubitemid 41125414)
56. Rhyner C, Kundig T, Akdis CA, Crameri R (2007) Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 35:833-834 (Pubitemid 47310379)
57. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ et al (2008) Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 105:17908-17912
58. Sigel MB, Sinha YN, VanderLaan WP (1983) Production of antibodies by inoculation into lymph nodes. Methods Enzymol 93:3-12 (Pubitemid 13069368)
59. Smith KA, Tam VL, Wong RM, Pagarigan RR, Meisenburg BL, Joea DK et al (2009) Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 27:2603-2615
60. Stewart GE, II, Lockey RF (1992) Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 90:567-578
61. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF (2004) Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172:1777-1785 (Pubitemid 38116826)
62. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S et al (2003) Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98:144-154 (Pubitemid 36741137)
63. Thomas R, Chambers M, Boytar R, Barker K, Cavanagh LL, MacFadyen S et al (1999) Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res 9:474-481 (Pubitemid 29494113)
64. Till SJ, Francis JN, Nouri-Aria K, Durham SR (2004) Mechanisms of immunotherapy. J Allergy Clin Immunol 113:1025-1034, quiz 35 (Pubitemid 38857978)
65. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR (1991) Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Bmj 302:265-269
66. Verlato G, Corsico A, Villani S, Cerveri I, Migliore E, Accordini S et al (2003) Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 111:1232-1238 (Pubitemid 36683675)
67. Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ (2004) Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol 113:1204-1210 (Pubitemid 38858007)
68. Von Beust BR, Johansen P, Smith KA, Bot A, Storni T, Kundig TM (2005) Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 35:1869-1876 (Pubitemid 40862335)
69. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M et al (2008) Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 31:215-223
70. Wuthrich B, Schindler C, Medici TC, Zellweger JP, Leuenberger P (1996) IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss study on air pollution and lung diseases in adults) Team. Int Arch Allergy Immunol 111:396-402 (Pubitemid 26390342)
71. Zinkernagel RM (2000) Localization dose and time of antigens determine immune reactivity. Semin Immunol 12:163-171, discussion 257-344 (Pubitemid 30479434)
72. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H (1997) Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156:199-209 (Pubitemid 27197203)